Get started
Author

Sébastien L. Degorce

Observed names: Degorce Sl, S. Degorce, S.L. Degorce, Seb Degorce, Sebastien Degorce, Sebastien L. Degorce, Sebastien L. Degorce (5164547), Sébastien L. Degorce, Sébastien Degorce
ORCID: 0000-0002-9478-5106
Observed ORCID: 0000-0002-9478-5106
OpenAlex ID: A5010517370
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}- N -methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
2021 · Jeffrey W. Johannes, Amber Balazs, et al. · Journal of Medicinal Chemistry · 164
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)
2018 · Kurt G. Pike, Bernard Barlaam, et al. · Journal of Medicinal Chemistry · 138
Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines
2018 · Sébastien L. Degorce, Michael S. Bodnarchuk, et al. · Journal of Medicinal Chemistry · 110
Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3
2015 · Scott Boyd, Joanna L. Brookfield, et al. · Journal of Medicinal Chemistry · 94
Discovery of ( R )-8-(1-(3,5-Difluorophenylamino)ethyl)- N , N -dimethyl-2-morpholino-4-oxo-4 H -chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers
2014 · Bernard Barlaam, Sabina Cosulich, et al. · Journal of Medicinal Chemistry · 90
Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase
2016 · Sébastien L. Degorce, Bernard Barlaam, et al. · Journal of Medicinal Chemistry · 79
Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2018 · Jeremy Karlin, Jasmine Allen, et al. · Molecular Cancer Therapeutics · 72
Lowering Lipophilicity by Adding Carbon: AzaSpiroHeptanes, a log D Lowering Twist
2019 · Sébastien L. Degorce, Michael S. Bodnarchuk, et al. · ACS Medicinal Chemistry Letters · 59
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma
2017 · James S. Scott, Sébastien L. Degorce, et al. · Journal of Medicinal Chemistry · 59
Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase
2020 · Sébastien L. Degorce, Omid Tavana, et al. · Journal of Medicinal Chemistry · 57
Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators
2015 · Sébastien L. Degorce, Andrew Bailey, et al. · Journal of Medicinal Chemistry · 46
Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat
2015 · James S. Scott, Andrew Bailey, et al. · ACS Medicinal Chemistry Letters · 44
Tricyclic Indazoles—A Novel Class of Selective Estrogen Receptor Degrader Antagonists
2019 · James S. Scott, Andrew Bailey, et al. · Journal of Medicinal Chemistry · 43
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}- N -methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor
2024 · Jeffrey W. Johannes, Amber Y. S. Balazs, et al. · Journal of Medicinal Chemistry · 36
Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R)
2016 · Sébastien L. Degorce, Scott Boyd, et al. · Journal of Medicinal Chemistry · 35
Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4
2018 · Sébastien L. Degorce, Rana Anjum, et al. · Bioorganic & Medicinal Chemistry · 24
Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88L265P Mutant Diffuse Large B Cell Lymphoma
2019 · Sébastien L. Degorce, Rana Anjum, et al. · Journal of Medicinal Chemistry · 22
Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours
2014 · Bernard Barlaam, Sabina Cosulich, et al. · Bioorganic & Medicinal Chemistry Letters · 20
Diversity-orientated synthesis of 3,5-bis(arylamino)pyrazoles
2011 · Sébastien Degorce, Frédéric H. Jung, et al. · Tetrahedron Letters · 19
Analyzing Compound and Project Progress Through Multi-Objective-Based Compound Quality Assessment
2013 · J Willem M Nissink, Sébastien Degorce · Future Medicinal Chemistry · 15
Design of rigid protein–protein interaction inhibitors enables targeting of undruggable Mcl-1
2023 · David Hargreaves, Rodrigo J. Carbajo, et al. · Proceedings of the National Academy of Sciences · 14
Facile, diversity-orientated one-pot synthesis of ethyl 1,5-disubstituted-1H-1,2,4-triazole-3-carboxylates
2012 · Sébastien Degorce, Bénédicte Delouvrié, et al. · Tetrahedron Letters · 13
Synthesis of novel, functionalised tricycles utilising the interrupted Pummerer reaction
2015 · Scott Boyd, Robert D.M. Davies, et al. · Tetrahedron Letters · 11
Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors
2020 · Sébastien L. Degorce, Anna Aagaard, et al. · Bioorganic & Medicinal Chemistry · 10
Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours
2016 · Bernard Barlaam, Sabina Cosulich, et al. · Bioorganic & Medicinal Chemistry Letters · 8
Works count: 75
Citation count: 1,342
H-index: 19
I10-index: 24
Year
Topic
Type